Bayes pulmonary embolism assisted-diagnosis: a new expert system for clinical use by Luciani, Davide et al.
doi:10.1136/emj.2006.037440 
 2007;24;157-164 Emerg. Med. J.
  
Massimo Pistolesi and Guido Bertolini 
Davide Luciani, Silvio Cavuto, Luca Antiga, Massimo Miniati, Simona Monti,
  
 new expert system for clinical use
Bayes pulmonary embolism assisted diagnosis: a
 http://emj.bmj.com/cgi/content/full/24/3/157
Updated information and services can be found at: 
 These include:
 References
  
 http://emj.bmj.com/cgi/content/full/24/3/157#BIBL
This article cites 35 articles, 19 of which can be accessed free at: 
Rapid responses
 http://emj.bmj.com/cgi/eletter-submit/24/3/157
You can respond to this article at: 
 service
Email alerting
top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at the
 Notes   
 http://www.bmjjournals.com/cgi/reprintform
To order reprints of this article go to: 
 http://www.bmjjournals.com/subscriptions/
 go to: Emergency Medicine JournalTo subscribe to 
 on 12 March 2007 emj.bmj.comDownloaded from 
ORIGINAL ARTICLE
Bayes pulmonary embolism assisted diagnosis: a new expert
system for clinical use
Davide Luciani, Silvio Cavuto, Luca Antiga, Massimo Miniati, Simona Monti, Massimo Pistolesi,
Guido Bertolini
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
See end of article for
authors’ affiliations
. . . . . . . . . . . . . . . . . . . . . . . .
Correspondence to:
Dr G Bertolini, GiViTI
Coordinating Center—
Istituto di Ricerche
Farmacologiche ‘‘Mario
Negri’’, Centro di Ricerche
Cliniche per le Malattie Rare
Aldo e Cele Dacco`, Ranica
(Bergamo) 24020, Italy;
bertolini@marionegri.it
Accepted
29 September 2006
. . . . . . . . . . . . . . . . . . . . . . . .
Emerg Med J 2007;24:157–164. doi: 10.1136/emj.2006.037440
Background: The diagnosis of pulmonary embolism demands flexible decision models, both for the presence
of clinical confounders and for the variability of local diagnostic resources. As Bayesian networks fully meet
this requirement, Bayes Pulmonary embolism Assisted Diagnosis (BayPAD), a probabilistic expert systems
focused on pulmonary embolism, was developed.
Methods: To quantitatively validate and improve BayPAD, the system was applied to 750 patients from a
prospective study done in an Italian tertiary hospital where the true pulmonary embolism status was confirmed
using pulmonary angiography or ruled out with a lung scan. The proportion of correct diagnoses made by
BayPAD (accuracy) and the correctness of the pulmonary embolism probabilities predicted by the model
(calibration) were calculated. The calibration was evaluated according to the Cox regression–calibration
model.
Results: Before refining the model, accuracy was 88.6%. Once refined, accuracy was 97.2% and 98%,
respectively, in the training and validation samples. According to Cox analysis, calibration was satisfactory,
despite a tendency to exaggerate the effect of the findings on the probability of pulmonary embolism. The lack
of some investigations (like Spiral computed tomographic scan and Lower limbs doppler ultrasounds) in the
pool of available data often prevents BayPAD from reaching the diagnosis without invasive procedures.
Conclusions: BayPAD offers clinicians a flexible and accurate strategy to diagnose pulmonary embolism.
Simple to use, the system performs case-based reasoning to optimise the use of resources available within a
particular hospital. Bayesian networks are expected to have a prominent role in the clinical management of
complex diagnostic problems in the near future.
D
espite the recent improvements in diagnostic methods for
thromboembolism, the diagnosis of pulmonary embolism
remains challenging.1–8 Reasons include the high cost of
accurate examinations, the different risk perception with
techniques based on contrast media (like pulmonary angio-
graphy,9 phlebography and spiral computed tomographic
scan10 11), and the variability in terms of practical availability
and even the performance of qualified people.12 13 Moreover,
some observations may have a negative or positive effect on the
value of further ascertainments, explaining why, for instance,
pulmonary embolism can be hard to diagnose in patients with
other cardiorespiratory diseases.14–17 Thus, the diagnosis of
pulmonary embolism cannot be made without combining and
interpreting a collection of investigations.18 One innovative
approach to see how different findings influence medical
hypotheses is offered by Bayesian or probabilistic networks.19 20
These can assist a decision flexibly, depending on the
examinations that are available among a large range of
choices.21 22 To exploit these innovations in the diagnosis of
pulmonary embolism, we developed Bayes Pulmonary embo-
lism Assisted Diagnosis (BayPAD), an evidence-based expert
system23 composed of a probabilistic network focused on
thromboembolic disease (fig 1). Once a patient’s findings are
entered, the model provides the probability of pulmonary
embolism and the information content of examinations still to
be carried out. The information content is related to the ability
of an examination to reduce the uncertainty about a diagnostic
hypothesis, and can be assessed by the mutual information
measure.24 The BayPAD suggestions are tailored to each
patient’s characteristics and each centre’s facilities. The system
was extensively validated through different steps, covering face
and content validity, and qualitative comparison with inde-
pendent experts’ suggestions.
Here we used the data collected in the Prospective
Investigative Study of Acute Pulmonary Embolism Diagnosis
(PISA-PED) study on the diagnosis of pulmonary embolism25 to
quantitatively validate and further improve the system. As
BayPAD was designed to help doctors in correctly classifying
suspected thromboembolic events, the primary index of
performance is diagnostic accuracy, split into its two dimen-
sions: sensitivity and specificity. Given that the model also
indicates the probability of the disease, we analysed the
‘‘calibration’’, which evaluates the degree of correspondence
between the estimated probability produced by the model and
the patient’s true disease status.
METHODS
Data
The PISA-PED study was a prospective observational study
completed at an Italian tertiary hospital in 1996 on 750
consecutive patients. Eligibility was based on the clinical
judgement of suspected pulmonary embolism according to six
on-call pulmonary doctors, all of whom had experience with
diagnosis of the disease.25 From the whole study population, a
first group of 500 patients were randomly selected to further
develop the model (training sample), with the second group of
250 patients employed only to evaluate the validity of the
refined model (validation sample). In all patients pulmonary
Abbreviations: BayPAD, Bayes Pulmonary embolism Assisted Diagnosis;
PISA-PED, Prospective Investigative Study of Acute Pulmonary Embolism
Diagnosis
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embolism was confirmed by pulmonary angiography, or was
ruled out when a lung scan showed no perfusional defects. In
the training sample, perfusion lung scans were normal or near
normal in 105 of 500 (21%) patients and abnormal in 395
(79%). Angiograms were positive for pulmonary embolism in
200 (40%) patients and negative in 191 (38%). In four patients
who died before angiography could be done, the diagnosis was
established at autopsy. Two of these patients had pulmonary
embolism. Patients were aged 63.8 (14.5) years (range
15–91 years); 243 (49%) of them were men. Most patients
(85%) were hospitalised at the time of study entry (table 1).26
Table 2 displays the variables of diagnostic interest the
BayPAD system is able to cope with, as well as those available
in the PISA-PED database.
As the BayPAD system had 48 variables and the PISA-PED
34, the model could not be validated completely. Regardless of
this limit, the bayesian characteristic of the network enables us
to deal with missing information, without the need to input any
observation merely because it is contemplated by the model.
This feature explains the adaptability of the system to the
diagnostic resources of a particular hospital or ward, and it is
also what makes this retrospective analysis methodologically
feasible.
Overall, six variables were present in the PISA-PED study but
not in our model. Five variables (‘‘chest pain’’, ‘‘pregnancy’’,
‘‘surgery’’, ‘‘electrocardiographic signs of right heart overload’’
and ‘‘pulmonary embolism’’) were expressed with more details
in the network than in the study (three-level v two-level
variables). To use the PISA-PED data, we simplified the
network in these variables. The opposite happened for ‘‘perfu-
sion lung scan’’, which was a three-level variable in the PISA-
PED Study (‘‘no perfusional defects’’, ‘‘segmental defect’’ and
‘‘not segmental defect’’) but binary in the original network
(‘‘normal’’ and ‘‘abnormal’’). The model was extended accord-
ingly. Eventually, 28 variables were available for the validation
analysis (table 2).
Data were processed following the algorithm through which
BayPAD implements its strategy (fig 2). The diagnostic criteria
are based on two probabilistic cut-offs: probability .95% to
confirm pulmonary embolism and ,5% to exclude pulmonary
embolism, provided that all the examinations whose costs
divided by the probability of pulmonary embolism do not exceed
a conventional boundary of J3500 were already done.23 Once
applied, these criteria become clearly asymmetric and more
sensitive to false negatives, as many diagnostic procedures
remain cost-sustainable even for probabilities ,5%. BayPAD
Figure 1 A simplified Bayesian network
showing the main pathophysiological
relationships in the diagnostic reasoning
focused on a suspected pulmonary embolism
event. For the sake of clarity, observable
findings have been given a generic label of
symptom, sign, test or risk factor, and their
association with the rest of the variables has
been omitted.
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suggests pulmonary angiography when the information content
of the examinations not carried out is too low to allow a
diagnostic conclusion (fig 2). As a result, we had the final
BayPAD diagnosis for each patient and one predicted probability
of pulmonary embolism for each patient step (fig 3, where the
algorithm has been applied to two real clinical examples).
Patients whose diagnosis was reached by asking for this
‘‘standard’’ were identified.
Hardware requirements for the analysis consist of a central
processing unit of at least 233 MHz and 64 Mb random access
memory.
Diagnostic performance
BayPAD’s ability to classify cases correctly was assessed from
sensitivity, specificity and overall diagnostic accuracy. We
computed these indicators for the whole sample and for the
subsample of patients whose diagnosis was reached without
pulmonary angiography.
To measure how well the model was calibrated, we adopted
the approach introduced by Cox.27 Labelling p the probabilities
computed by the model, a logistic regression was done with the
outcome of pulmonary embolism as the dependent variable and
the natural logarithm transformation of the ratio p/(1-p) as the
independent regressor (ie, the ordinary logit transformation). If
the accuracy of p is faultless, the estimates of the intercept and
the slope are 0 and 1, respectively. An intercept different from 0
would show a systematic disagreement between the probabil-
ities produced by the model and the proportion of pulmonary
embolism cases. A positive slope lower or higher than 1 would
show the predicted probabilities, respectively, increasing or
decreasing compared with the observed density of pulmonary
embolism events. A null slope would mean that predicted
probabilities are completely independent of the outcomes,
whereas a negative slope would prove a negative association.28
Finally, a calibration curve was drawn by plotting deciles of
predicted probabilities against the corresponding proportion of
pulmonary embolism events.
Refinement and validation of the model
As diagnostic accuracy is sensitive to biases affecting predicted
probabilities, the network was refined by looking at its
calibration in the 500 cases representing the training sample.
We followed the approach suggested by Miller et al.28 Firstly, a
sensitivity analysis was performed by excluding cases with
identical characteristics. As a result, each case was associated
with a measure of its effect on calibration, considering both Cox
parameters. Secondly, these measures played the part of
dependent variable in two separate linear regression models,
where the influential patient’s characteristics (on calibration)
were identified. Finally, the network parameters related to
these characteristics were reappraised and tuned, keeping a
modification only when it conformed to the medical literature
and enhanced the validity of the model. As the structure of the
network represents the cause–effect relationships among
variables (fig 1), if an improvement was attainable with
structural changes, these were discussed and allowed only if
consistent with the pathophysiological understanding of
pulmonary embolism. Such a conservative approach in chan-
ging the probabilistic network was adopted to reduce the
chance of overfitting the PISA-PED data. The process was
repeated until influential variables and convincing refinements
could be detected.
Diagnostic performance was evaluated on both the original
and the refined model, with the additional employment of a
validation (250 cases) sample as it concerns the latter.
RESULTS
The original network
Among the 500 cases provided by the training sample, there
were 40.4% of pulmonary embolism cases. BayPAD made a
correct diagnosis in 88.6% of the cases (accuracy), with 17 false
negative and 40 false positive cases. This figure can be divided
into 91.6% (95% CI 86.9 to 94.7) cases of correct diagnosis
among true pulmonary embolism cases (sensitivity) and 86.6%
(95% CI 82.2 to 90) cases of correct diagnosis among truly non-
pulmonary embolism cases (specificity); 152 (30.4%) cases
required pulmonary angiography to reach the final diagnosis.
In the subgroup in which pulmonary angiography was not
used, accuracy was 83.6%, sensitivity 88.8% and specificity
79.6%.
When the BayPAD strategy was applied to the data, each case
passed through an average of 3.3 further ascertainments before
the final diagnosis, producing a total of 1660 steps where
predicted probabilities were computed. Cox analysis indicated
that the intercept was 20.234 (95% CI –0.364 to –0.104),
significantly different from 0 (p,0.001), and the slope 0.2091
(95% CI 0.182 to 0.236), significantly different from 1
(p,0.001).
The refined network
Several phases of parameter tuning were done to increase the
validity of the model. Most of them affected the quantitative
strength of associations between variables, and others the
increase in the number of discrete intervals for continuous
variables (like paO2 and paCO2). Structural changes were
introduced to account for previously neglected associations, like
that for ‘‘bone fractures’’, found to be an extra explanation of
‘‘unilateral oedema’’.
After refinement, BayPAD showed 97.2% accuracy in the 500
cases of the training sample, with six false-negative and eight
false-positive cases. Sensitivity and specificity were 97.0% (95%
CI 94.2 to 98.7) and 97.3% (95% CI 95.2 to 98.7); 187 (37%)
cases required pulmonary angiography to reach the final
diagnosis. Accuracy was 96.0%, with 96.0% sensitivity and
95.9% specificity in the subgroup in which pulmonary
angiography was not needed.
Concerning calibration, the intercept and slope of the Cox
approach were, respectively, –0.05 (95% CI –0.08 to 0.18), not
significantly different from 0 (p = 0.47), and 0.62 (95% CI 0.56
to 0.68), significantly different from 1 (p,0.001).
Figure 4 shows the calibration curve of the refined model.
Each decile had more than five expected cases of pulmonary
embolism.
The validation sample showed a proportion of pulmonary
embolism cases (41.6%) comparable to that which emerged
from the training sample. BayPAD delivered an accurate
Table 1 Characteristics of the first 500 patients enrolled in
the Prospective Investigative Study of Acute Pulmonary
Embolism Diagnosis Study
n (%)
Dyspnoea 345 (69)
Chest pain 240 (48)
Fainting 91 (18)
Palpitations 82 (16)
Hospitalisation 437 (85)
Surgery* 197 (39)
Bone fractures (lower limbs)* 82 (16)
Pre-existing diseases
Cardiovascular 149 (30)
Pulmonary 86 (17)
Neoplastic 79 (16)
Endocrine 53 (11)
*Within 4 weeks of study entry.
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Table 2 Variables selected in the validation analysis
Variables BayPAD included in the networkAvailable in the PISA-PED StudySelected for the validation
Pre-existing disease
Chronic cardiovascular disease Yes Yes Yes
Chronic pulmonary disease Yes Yes Yes
Cancer Yes Yes Yes
Hereditary DVT predisposing factors Yes No No
Risk factors
Age Yes Yes Yes
Sex Yes Yes Yes
Immobilisation Yes Yes Yes
Cigarette smoking Yes No No
Central line Yes No No
Surgery Yes Yes Yes
Pregnancy Yes Yes Yes
Chronic venous insufficiency Yes Yes Yes
Oestrogen intake Yes Yes Yes
Bone fractures Yes Yes Yes
DVT prophylaxis Yes No No
Symptoms
Dyspnoea Yes Yes Yes
Orthopnoea Yes Yes Yes
Fainting Yes Yes Yes
Chest pain Yes Yes Yes
Haemoptysis Yes Yes Yes
Agitation Yes No No
Lower limb discomfort Yes No No
Cough Yes No No
Signs
Lower limb unilateral oedema Yes Yes Yes
Cyanosis Yes No No
Fever.38 C˚ No Yes No
Bronchospasmus Yes Yes Yes
Systolic blood pressure Yes No No
Tachypnoea Yes Yes Yes
Tachycardia No Yes No
Cardiac failure signs Yes Yes Yes
Shock Yes No No
Laboratory findings
D-dimer test Yes No No
paO2 Yes Yes Yes
paCO2 Yes Yes Yes
CK-MB enzymes Yes No No
ECG findings
ECG right heart overload signs Yes Yes Yes
ECG acute myocardial infarction signs Yes No No
Chest x rays
Consolidation (infarction) Yes Yes Yes
Consolidation (no infarction) No Yes No
Plate-like atelectasis No Yes No
Pulmonary oedema Yes Yes Yes
Elevation of half of the diaphragm Yes Yes Yes
Unilateral pleural effusion Yes No No
Pulmonary oligaemia No Yes No
Amputation of hilar artery No Yes No
Pneumonia Yes No No
Imaging
Doppler ultrasounds of the lower limbs Yes No No
Echocardiographic signs of pulmonary embolism Yes No No
Ventilation/perfusion lung scan Yes No No
Perfusion lung scan Yes Yes Yes
Phlebography Yes No No
Spiral CT scan Yes No No
Pulmonary angiography Yes Yes Yes
BayPAD, Bayes Pulmonary embolism Assisted Diagnosis; CK-MB, Creatine Kinase; CT, Computed tomography; DVT, Deep venous thrombosis; ECG, electrocardiogram;
PISA-PED, Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis.
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diagnosis in 98% of the 250 cases, with four false-negative and
one false-positive cases. Sensitivity and specificity were 96.1%
and 99.3%; pulmonary angiography was required for 79 (31%)
cases. Sensitivity and specificity were 94.5% and 98.9% in the
subgroup in which pulmonary angiography was not needed.
The intercept and slope of the Cox regression–calibration model
were, respectively, 0.31 (95% CI 0.10 to 0.52), significantly
different from 0 (p = 0.003), and 0.70 (95% CI 0.61 to 0.80),
significantly different from 1 (p,0.001).
DISCUSSION
BayPAD is an expert system based on a probabilistic network
whose structure represents the ‘‘state of the art’’ on the
pathophysiological understanding of thromboembolism (fig 1).
Thus, within its automated diagnostic reasoning, the system
acknowledges which part of the network is relevant to a
decision, given the specific patient’s findings. On the basis of
the causal relationships between events, a virtually infinite
number of clinical scenarios can be dealt with, whereas the
computation to identify the most appropriate examination
takes just a few milliseconds.19 Conversely, in guidelines based
on decision trees, whether or not an examination is appropriate
is established through a limited set of predefined patient’s
findings. So if the performance of these algorithms proves to be
satisfactory at a population level, they are often inappropriate
when applied to the clinical investigation of individual
problems.29
The other popular aid to medical diagnosis is scoring systems,
indicating the need for further ascertainments according to the
predicted probability of the diagnosis. However, they overlook
the possible influence of available findings on the results of the
examinations suggested. As an example, recent surgery
increases the risk of pulmonary embolism, but it also reduces
the specificity of the D-dimer test 30; again, previous cardio-
pathy makes an echocardiography or an ECG more sensitive to
an embolic episode, because in these patients a haemodyna-
mically relevant pulmonary embolism is more likely.17 31 In the
BayPAD model, these phenomena are taken into account.
Finally, the Bayesian nature of the probabilistic network allows
BayPAD to deal with missing information.32
The consequent flexibility makes it possible to deal with the
problem of optimal exploitation of available diagnostic
resources. This is important, as resources are usually so
differently distributed among the clinical settings where
pulmonary embolism is a challenge that it is hard to expect
widespread acceptance of any guideline on the basis of a fixed
set of examinations.13 The potential value of probabilistic
networks in this field has been theoretically accepted,21 22 33
but their successful application obviously depends on their
diagnostic accuracy over different contexts. Usually, to validate
a prediction model, all the variables considered must be
collected, without missing. However, a Bayesian Network can
be regarded as the assemblage of smaller networks, allowing
independent validation of each part. Such an approach is safe
Figure 2 The Bayes Pulmonary embolism
Assisted Diagnosis (BayPAD) strategy: the
algorithm implementing the BayPAD
diagnostic strategy on the PISA-PED cases.
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as long as the structure of the network represents the causal
relationships among the events included in the model.34
Consequently, even a quite old database like PISA-PED is of
value for a validation purpose. Indeed, although some
important tests are lacking (eg, computed tomographic scan
or D-dimer), the PISA-PED data allowed the assessment of the
most complex part of the model. Moreover, since in a Bayesian
Network the overall proportion of an event depends on the
conditional observations included, the large set of variables
considered in BayPAD makes the possible difference between
the validation sample and another population of interest
relatively unimportant. As a matter of fact, BayPAD, after its
refinement based on the PISA-PED data, still returns a
proportion of pulmonary embolism cases before any observa-
tion is introduced which is around 1%. This resembles the
prevalence of pulmonary embolism in a general hospital, rather
than the prevalence expected given a clinical suspicion of
pulmonary embolism, like in the PISA-PED study.
Here the assessment of the system passed through the
evaluation of two major properties: predicting a reliable
probability of pulmonary embolism for a specific patient, and
distinguishing between true and false cases of pulmonary
embolism. These are closely related, as the second is obtained
through a couple of probabilistic cut-offs that are expected to be
reliable. Therefore, the calibration of BayPAD has been
examined first, providing the only evidence used to refine the
model.
Rather than looking at a qualitative response in the
calibration of our model, like within a significance testing
framework,35 36 our aim was to see how accurate the prob-
abilities predicted by the model were. The approach introduced
Figure 3. Bayes Pulmonary embolism Assisted Diagnosis (BayPAD) working with two real clinical examples. The algorithm steps presented in fig 2 are
indicated in brackets.
Figure 4 The calibration curve with observed probabilities (frequencies)
of pulmonary embolism events plotted against predicted probabilities of the
same event. Data are grouped into deciles according to the predicted
probabilities. The dotted line represents perfect calibration, whereas the
green (with triangles) and the blue (with squares) curves, respectively, refer
to the training and validation samples.
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by Cox provided us with this quantitative insight.27 Once
applied to the original network, the analysis gave an intercept
of –0.23, meaning that, on average, the probability of
pulmonary embolism exceeded its observed frequency.
Instead, the slope of 0.21 showed a tendency of the low
probabilities to be too low and that of the high probabilities to
be too high, resulting in overconfidence in the diagnosis.
Looking at the effect of this calibration on the diagnostic
accuracy in the studied population, we found correct classifica-
tion for 88.6% of the suspected cases.
The complete independence of the PISA-PED study from the
development of the model, the heterogeneity of the sources in
the medical literature fuelling the network’s knowledge37 and
the qualitative assessment of the network’s behaviour as its sole
former validation23 make this figure encouraging. However, this
estimation is also inconsistent with the probabilistic values
adopted to authorise a diagnosis, which would allow ,10% of
diagnostic errors. As expected, this inadequacy was treated as a
model recalibration problem. After the refinement analysis, the
slope parameter moved near to its ideal value of 1, both in the
training and in the validation sample (0.62 and 0.70,
respectively). This means that the original tendency to
exaggerate the effect of the observations on the pulmonary
embolism hypothesis has been greatly reduced. The intercept
parameter, on the other hand, shows that, in the validation
sample, the predicted probabilities tend to be overall too low.
Particularly, an intercept of 0.3 entails for predicted probability
around 50% to be undersized of 7%.
How the residual bias affects the diagnostic accuracy is easily
visualised on the calibration curve (fig 4). Misclassified cases
became ,10% (2.8% and 2%, respectively, in the training and
validation samples), and this remains true when accuracy was
measured in the 347 cases where pulmonary angiography was
not suggested (4%). The lack of important investigations in the
pool of available data (table 2) often prevented BayPAD from
suggesting minimally invasive but still informative tests, with
the result that pulmonary angiography was suggested for about
one third of the patients. The many investigations not
contemplated in the PISA-PED study include Doppler ultra-
sound of the lower limbs, echocardiography, D-dimer and spiral
computed tomographic scan. As these procedures are available
in most hospitals, the resulting proportion of pulmonary
angiography seems not to reflect the behaviour of BayPAD,
once introduced in the clinical setting (eg, fig 3 shows two real
cases where BayPAD evaluates the appropriateness of D-dimer
and spiral computed tomographic scan). Moreover, given the
progress achieved by the latest multidetector computed tomo-
graphic scans,38 this technique is expected to replace pulmonary
angiography in most instances, while still supporting the
diagnostic engine with similar precision. To confirm this, we
simulate the effect of the availability of a computed tomo-
graphic scan with 0.92 sensibility and 0.98 specificity,3 6
obtaining a correct diagnosis in 96% of all cases.
The literature offers a number of diagnostic strategies for the
diagnosis of pulmonary embolism,25 39–44 but it is hard to
compare their performances. Studies to validate the proposed
algorithms apply different procedures to check the true
diagnosis25 43: some are focused on the prognostic outcome
rather than the diagnostic classification.42 44 They mostly differ
in terms of available diagnostics,25 39–41 43 and classify patients
according to a variable number of pulmonary embolism
probability levels.25 40
Without perfusion lung scan, but with a clinical assessment
extended to chest x rays, ECG and arterial blood samples,
Miniati et al found their algorithm correct in 90% of suspected
cases.25 On the basis of similar findings, but with the inclusion
of the ventilation/perfusion lung scan and bilateral leg vein
ultrasonography, the Wells score correctly identified 96% of
cases.39 Another study showed a predictive accuracy for the
Geneva score and a simplified version of the Wells score, both
based on clinical findings alone, of 78% and 74%, respectively.40 41
The BayPAD system deals with most of the issues raised by a
complex diagnostic problem like pulmonary embolism. To the
best of our knowledge, this is the first validated clinical model
where the choice of a new ascertainment depends on its
information content.24 45 Moreover, the probabilistic network
underlying the expert system covers the largest set of
examinations ever contemplated for the disease. This already
enables BayPAD to deal with hypotheses other than pulmonary
embolism. Such a possibility will be fully exploited in a future
version, where the most appropriate ascertainment will depend
on a broad spectrum of possible diagnoses, without privileging
pulmonary embolism. Growing to be a multi-purpose system,
BayPAD could be accepted even in the emergency department,
where time constraints and overcrowding often hamper the use
of computer-based systems.
Although a prospective investigation is still needed to
evaluate BayPAD in its full potential, the results obtained with
this model, even at an initial phase of its development, reserve
for Bayesian networks a prominent role in the next generation
of clinical decision models. This prospect sounds like a proper
reply to some farsighted authors who, like Feinstein, 10 years
ago advocated ‘‘appropriate scientific analyses for the unique
and fundamental characteristics of clinical activities that still
occur as ‘clinical judgement’’’.46
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